Latest VR Adviser, LLC Stock Portfolio
VR Adviser, LLC Performance:
2025 Q4: 41.33%YTD: 58.45%2024: 2.55%
Performance for 2025 Q4 is 41.33%, and YTD is 58.45%, and 2024 is 2.55%.
About VR Adviser, LLC and 13F Hedge Fund Stock Holdings
VR ADVISER, LLC is a hedge fund based in New York, NY. On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, VR ADVISER, LLC reported an equity portfolio of $2 Billions as of 31 Dec, 2025.
The top stock holdings of VR ADVISER, LLC are , , VRDN. The fund has invested 31.7% of it's portfolio in APOGEE THERAPEUTICS INC and 6.2% of portfolio in ORUKA THERAPEUTICS INC.
The fund managers got completely rid off METSERA INC, CIDARA THERAPEUTICS INC (CDTX) and ASTRIA THERAPEUTICS INC (ATXS) stocks. They significantly reduced their stock positions in COGENT BIOSCIENCES INC (COGT), OCULAR THERAPEUTIX INC (OCUL) and ORIC PHARMACEUTICALS INC (ORIC). VR ADVISER, LLC opened new stock positions in CYBIN INC (CYBN). The fund showed a lot of confidence in some stocks as they added substantially to VOR BIOPHARMA INC (VOR), CRESCENT BIOPHARMA INC. and SPYRE THERAPEUTICS INC (AGLE).
The top stock holdings of VR ADVISER, LLC are , , VRDN. The fund has invested 31.7% of it's portfolio in APOGEE THERAPEUTICS INC and 6.2% of portfolio in ORUKA THERAPEUTICS INC.
The fund managers got completely rid off METSERA INC, CIDARA THERAPEUTICS INC (CDTX) and ASTRIA THERAPEUTICS INC (ATXS) stocks. They significantly reduced their stock positions in COGENT BIOSCIENCES INC (COGT), OCULAR THERAPEUTIX INC (OCUL) and ORIC PHARMACEUTICALS INC (ORIC). VR ADVISER, LLC opened new stock positions in CYBIN INC (CYBN). The fund showed a lot of confidence in some stocks as they added substantially to VOR BIOPHARMA INC (VOR), CRESCENT BIOPHARMA INC. and SPYRE THERAPEUTICS INC (AGLE).
VR Adviser, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that VR ADVISER, LLC made a return of 41.33% in the last quarter. In trailing 12 months, it's portfolio return was 58.45%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| cybin inc | 31,413,200 |
New stocks bought by VR Adviser, LLC
Additions
| Ticker | % Inc. |
|---|---|
| vor biopharma inc | 288 |
| crescent biopharma inc. | 53.73 |
| spyre therapeutics inc | 37.24 |
| maze therapeutics inc | 25.82 |
| zura bio ltd | 15.41 |
| savara inc | 8.35 |
| dianthus therapeutics inc | 4.08 |
Additions to existing portfolio by VR Adviser, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| cogent biosciences inc | -50.00 |
| ocular therapeutix inc | -44.42 |
| oric pharmaceuticals inc | -13.96 |
| engene holdings inc | -5.45 |
VR Adviser, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| metsera inc | -196,272,000 |
| astria therapeutics inc | -17,889,500 |
| cidara therapeutics inc | -90,664,400 |
| perceptive cap solutions cor | -7,950,000 |
| pharvaris n v | -16,831,200 |
| abivax sa | -48,964,300 |
| tenax therapeutics inc | -3,330,960 |
VR Adviser, LLC got rid off the above stocks
Sector Distribution
VR ADVISER, LLC has about 54.6% of it's holdings in Others sector.
- Others
- Healthcare
| Sector | % |
|---|---|
| Others | 54.6 |
| Healthcare | 45.4 |
Market Cap. Distribution
VR ADVISER, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- SMALL-CAP
- MID-CAP
- MICRO-CAP
| Category | % |
|---|---|
| UNALLOCATED | 54.6 |
| SMALL-CAP | 22.6 |
| MID-CAP | 20.8 |
| MICRO-CAP | 2 |
Stocks belong to which Index?
About 35.4% of the stocks held by VR ADVISER, LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 64.6 |
| RUSSELL 2000 | 35.4 |
VR Adviser, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of VR Adviser, LLC
VR ADVISER, LLC has 27 stocks in it's portfolio. About 73.7% of the portfolio is in top 10 stocks. VOR proved to be the most loss making stock for the portfolio. was the most profitable stock for VR ADVISER, LLC last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AGLE | spyre therapeutics inc | 5.96 | 3,685,450 | 120,735,000 | added | 37.24 | ||
| ATXS | astria therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTE | jade biosciences inc | 2.45 | 3,220,360 | 49,690,200 | unchanged | 0.00 | ||
| CDTX | cidara therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CGEM | cullinan therapeutics inc | 0.70 | 1,379,960 | 14,282,600 | unchanged | 0.00 | ||
| COGT | cogent biosciences inc | 3.51 | 2,000,000 | 71,040,000 | reduced | -50.00 | ||
| CTMX | cytomx therapeutics inc | 3.27 | 15,561,500 | 66,292,000 | unchanged | 0.00 | ||
| CYBN | cybin inc | 1.55 | 3,840,250 | 31,413,200 | new | |||
| DYN | dyne therapeutics inc | 2.10 | 2,173,910 | 42,521,700 | unchanged | 0.00 | ||
| ERAS | erasca inc | 3.28 | 17,857,100 | 66,428,300 | unchanged | 0.00 | ||
| KALV | kalvista pharmaceuticals inc | 5.37 | 6,728,980 | 108,673,000 | unchanged | 0.00 | ||
| OCUL | ocular therapeutix inc | 4.39 | 7,315,550 | 88,810,700 | reduced | -44.42 | ||
| ORIC | oric pharmaceuticals inc | 2.29 | 5,676,230 | 46,431,600 | reduced | -13.96 | ||
| PHVS | pharvaris n v | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| SRZN | surrozen inc | 0.71 | 632,931 | 14,304,200 | unchanged | 0.00 | ||
| SVRA | savara inc | 4.09 | 13,740,400 | 82,854,500 | added | 8.35 | ||
| TENX | tenax therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| VOR | vor biopharma inc | 1.26 | 1,943,770 | 25,424,500 | added | 288 | ||
| VRDN | viridian therapeutics inc | 5.97 | 3,882,710 | 120,830,000 | unchanged | 0.00 | ||
| apogee therapeutics inc | 31.67 | 8,493,320 | 641,076,000 | unchanged | 0.00 | |||